EVOSEP and ReSyn Biosciences partner to integrate their technologies into new clinical proteomics solutions

The ability to process large and clinically relevant cohorts in a robust and high-throughput manner is important to unlocking the full potential of proteomics for precision medicine. The latest generation of mass spectrometers allows for highly sensitive and high throughput proteome profiling, shifting the emphasis to robust sample preparation and separation. The aim being to provide seamless sample to mass spectrometer solutions that are both sensitive and simple to implement, with the throughput required to meet the needs of clinical applications in proteomics

ReSyn Biosciences and Evosep have recently demonstrated several joint solutions that integrate automated sample purification with liquid chromatography coupled mass spectrometry. They are currently expanding the collaboration to provide further innovative solutions by announcing that Dr. Stoyan Stoychev, who leads the proteomics applications development at ReSyn Biosciences, will be co-joining the applications development team at Evosep, with the aim of accelerating developments in this field.

 “We are excited about this joint appointment and believe that it will lead to better integrations of our technologies in solutions that meet the needs of the emerging field of clinical proteomics”.

Dr. Justin Jordaan, CEO & CSO, ReSyn Biosciences.

ReSyn’s expertise with bead-based workflows fits perfectly with Evosep’s ambition of standardizing and automating end-to-end proteomic workflows. We share the goal of developing standardized and modular end-to-end workflows that consists of individual functional units that can be added or removed as needed to collectively define different end-to-end workflows. Stoyan has extensive experience in this space and through this shared position, he will be a central part of developing and supporting solutions that drive proteomics towards clinical use.”

Dr. Nicolai Bache, Head of Applications, Evosep.

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Evosep. (2023, March 14). EVOSEP and ReSyn Biosciences partner to integrate their technologies into new clinical proteomics solutions. News-Medical. Retrieved on July 24, 2024 from https://www.news-medical.net/news/20230314/EVOSEP-and-ReSyn-Biosciences-partner-to-integrate-their-technologies-into-new-clinical-proteomics-solutions.aspx.

  • MLA

    Evosep. "EVOSEP and ReSyn Biosciences partner to integrate their technologies into new clinical proteomics solutions". News-Medical. 24 July 2024. <https://www.news-medical.net/news/20230314/EVOSEP-and-ReSyn-Biosciences-partner-to-integrate-their-technologies-into-new-clinical-proteomics-solutions.aspx>.

  • Chicago

    Evosep. "EVOSEP and ReSyn Biosciences partner to integrate their technologies into new clinical proteomics solutions". News-Medical. https://www.news-medical.net/news/20230314/EVOSEP-and-ReSyn-Biosciences-partner-to-integrate-their-technologies-into-new-clinical-proteomics-solutions.aspx. (accessed July 24, 2024).

  • Harvard

    Evosep. 2023. EVOSEP and ReSyn Biosciences partner to integrate their technologies into new clinical proteomics solutions. News-Medical, viewed 24 July 2024, https://www.news-medical.net/news/20230314/EVOSEP-and-ReSyn-Biosciences-partner-to-integrate-their-technologies-into-new-clinical-proteomics-solutions.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Evosep receives strategic investment from Novo Holding A/S to accelerate its effort on clinical proteomics